熱門資訊> 正文

赛诺菲获得欧盟对Scarlisa皮下版本的批准建议

2026-03-27 22:56

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of a subcutaneous formulation of Sanofi's (SNY) Scarlisa (isatuximab) administered via on-body injection.
If approved, Scarlisa would become the only oncologic approved in the EU via an on-body injection.
Scarlisa is approved for multiple myeloma.

More on Sanofi

Dupixent's Impact On Sanofi: A Quantitative Projection Of Its Revenue
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi replaces CEO Paul Hudson, names Belén Garijo as successor
Sanofi anticipates profitable growth to continue over at least five years

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。